Entinostat (MS-275)

Name: Entinostat (MS-275)
Brand: Selleck Chemicals
SKU: S1053
Rating: 5 (271 reviews)

For research use only. Not for use in humans.

Catalog No.S1053 Synonyms: SNDX-275

271 publications

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Selleck's Entinostat (MS-275) has been cited by 271 publications

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Gastroenterology, 2019, 156(1):187-202

PubMed: 30267710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5324

PubMed: 31757943 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz1136

PubMed: 31799598 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(5):1005-1025

PubMed: 30599067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

Br J Cancer, 2019, 121(12):1039-1049

PubMed: 31690832 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 10:409

PubMed: 30915074 ( click the link to review the publication )
Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

J Immunol, 2019, 203(12):3199-3208

PubMed: 31732526 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31694931 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(4):317-328

PubMed: 30668714 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108570

PubMed: 31054509 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Cancer Biol Ther, 2019, 20(5):700-710

PubMed: 30571927 ( click the link to review the publication )

Dev Biol, 2019, 449(2):122-131

PubMed: 30826398 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):669-682

PubMed: 30849634 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(3):e0213186

PubMed: 30830950 ( click the link to review the publication )

Pain Res Manag, 2019, 2019:1648919

PubMed: 30809320 ( click the link to review the publication )

Oncotarget, 2019, 10(20):1903-1917

PubMed: 30956773 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j.jcmgh.2019.10.005

PubMed: 31654770 ( click the link to review the publication )

eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )
Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):623

PubMed: 29795376 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Arch Toxicol, 2018, 92(7):2227-2243

PubMed: 29845424 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Oncoimmunology, 2018, 7(11):e1466018

PubMed: 30377559 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2018, 1864(8):2610-2622

PubMed: 29684588 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)

PubMed: 30424007 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13638

PubMed: 30206377 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9391

PubMed: 29925922 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )
Biochem J, 2018, 475(24):3921-3932

PubMed: 30552170 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(1):65-75

PubMed: 29721849 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194661

PubMed: 29579087 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):1967-1974

PubMed: 30008890 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467324 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Cond Med, 2018, 1(2):64-72

PubMed: 30135960 ( click the link to review the publication )

Oncotarget, 2018, 9(28):19597-19612

PubMed: 29731968 ( click the link to review the publication )

Oncotarget, 2018, 9(63):32182-32190

PubMed: 30181808 ( click the link to review the publication )

Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2235-2248

PubMed: 28436940 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(51):E10981-E10990

PubMed: 29203668 ( click the link to review the publication )

Cell Rep, 2017, 19(4):875-889

PubMed: 28445736 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(21):3865-3880

PubMed: 28832971 ( click the link to review the publication )
J Med Chem, 2017, 60(13):5334-5348

PubMed: 28581289 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2689-2700

PubMed: 28802253 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2017, 6:54-65

PubMed: 28664166 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Virol, 2017, 91(16)

PubMed: 28566376 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12084

PubMed: 28935977 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8641

PubMed: 28819194 ( click the link to review the publication )

Mech Ageing Dev, 2017, 166:6-15

PubMed: 28843433 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017, 76(12):1000-1007

PubMed: 29136455 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2017, 312(3):F502-F515

PubMed: 28052874 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Int J Mol Med, 2017, 40(3):661-672

PubMed: 28677722 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )
Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

Oncotarget, 2017, 8(69):114156-114172

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3172-3187

PubMed: 29423038 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83155-83170

PubMed: 29137331 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4079-4095

PubMed: 27863422 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:375-385

PubMed: 27761836 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Sci Signal, 2016, 9(422):ra34

PubMed: 27048565 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:62

PubMed: 27231489 ( click the link to review the publication )

Oncoimmunology, 2016, 5(11):e1219008

PubMed: 27999738 ( click the link to review the publication )

Oncoimmunology, 2016, 5(6):e1164919

PubMed: 27471639 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )
Mol Cancer Ther, 2016, 15(2):299-312

PubMed: 26772204 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Dis Model Mech, 2016, 9(5):541-52

PubMed: 26989193 ( click the link to review the publication )

J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

Front Cell Neurosci, 2016, 10:221

PubMed: 27729849 ( click the link to review the publication )

Front Cell Neurosci, 2016, 9:510

PubMed: 26793062 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Biol Chem, 2016, 397(1):75-83

PubMed: 26431101 ( click the link to review the publication )

Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Gene Regul Syst Bio, 2016, 10:9-13

PubMed: 26823649 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )
Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26701908 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Toxicol Sci, 2015, 148(1):220-8

PubMed: 26251326 ( click the link to review the publication )

Sci Rep, 2015, 5:16873

PubMed: 26585834 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )
Front Neurosci, 2015, 9:319

PubMed: 26441495 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 151(2):281-94

PubMed: 25904215 ( click the link to review the publication )

Virology, 2015, 485:340-54

PubMed: 26331681 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144660

PubMed: 26713848 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137699

PubMed: 26361334 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1441-53

PubMed: 24463822 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )
Retrovirology, 2014, 11:67

PubMed: 25116364 ( click the link to review the publication )

Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106784

PubMed: 25198282 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4516-28

PubMed: 24980831 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(28):E2621-8

PubMed: 23788661 ( click the link to review the publication )

Genet Mol Biol, 2013, 36(3):299-307

PubMed: 24130434 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2076-86

PubMed: 23047626 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )
Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

Pediatr Nephrol, 2013, 28(10):1909-21

PubMed: 23052657 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2012, 22(9):651-6

PubMed: 22341945 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

J Virol, 2012, 86(6):3073-87

PubMed: 22238308 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41776

PubMed: 22848598 ( click the link to review the publication )

Biochem Biophys Res Commun, 2012, 428(1):121-6

PubMed: 23063976 ( click the link to review the publication )

Biomol Ther (Seoul), 2012, 20(1):81-8

PubMed: 24116279 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )
J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

J Biomed Biotechnol, 2011, 2011:371832

PubMed: 21151613 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Targets

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21^WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. ^[1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. ^[2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
SCC-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnntTWM2OD1yLkC2NUDPxE1?	NGf1dGdUSU6JRWK=
ALL-PO	NIDFNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnsTWM2OD1yLkC2N\|U2KM7:TR?=	MkDoV2FPT0WU
697	NFn1[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;kfWlEPTB;MD6wPVk4PiEQvF2=	M2nNT3NCVkeHUh?=
NCI-H748	Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMUCzN\|Qh\|ryP	M2SxZ3NCVkeHUh?=
NKM-1	MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMUC5NVIh\|ryP	MnKzV2FPT0WU
ES1	NIXNNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMUGyOVUh\|ryP	NWj5ZmZJW0GQR1XS
NCI-H1963	NF;PS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwMUG1O\|kh\|ryP	MVfTRW5ITVJ?
NCI-H1417	M{KxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjlephKSzVyPUCuNVI6PzRizszN	MmThV2FPT0WU
NEC8	M1PpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPMdYJKSzVyPUCuNVM2OjdizszN	NX\nZppsW0GQR1XS
CRO-AP2	MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlizTWM2OD1yLkG2PFg6KM7:TR?=	M1vkNXNCVkeHUh?=
A3-KAW	M3;scGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1r5VmlEPTB;MD6xO\|YzPyEQvF2=	NE\TR4hUSU6JRWK=
SF539	NUnycoV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHqTWM2OD1yLkG5OVk{KM7:TR?=	NFjKR25USU6JRWK=
NOS-1	M3:2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;Jb4lKSzVyPUCuNVk3OTlizszN	M1TTVnNCVkeHUh?=
NTERA-S-cl-D1	NHnzUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rzUWlEPTB;MD6yNFEyOyEQvF2=	MWrTRW5ITVJ?
COR-L88	MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nab2lEPTB;MD6yNlk2QSEQvF2=	NXfh[5RIW0GQR1XS
EM-2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMkSwO\|kh\|ryP	MVPTRW5ITVJ?
KARPAS-45	Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjnRVhKSzVyPUCuNlc5OzNizszN	NWjvN4ZzW0GQR1XS
DSH1	NX;MWVdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmC5TWM2OD1yLkK4O\|A5KM7:TR?=	MlPYV2FPT0WU
HT-144	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwM{CyOVYh\|ryP	NYLU[HBbW0GQR1XS
ATN-1	MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fpZ2lEPTB;MD6zNFU4PiEQvF2=	MnfHV2FPT0WU
HEL	NV\CZmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwM{GzOFgh\|ryP	MX;TRW5ITVJ?
NB12	M3zFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rkSmlEPTB;MD6zNVc2PiEQvF2=	MoXRV2FPT0WU
LU-139	MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XFTWlEPTB;MD6zN\|UyKM7:TR?=	M3njPXNCVkeHUh?=
J-RT3-T3-5	Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFW2cm9KSzVyPUCuN\|M4OTZizszN	MUTTRW5ITVJ?
MOLT-13	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHvTWM2OD1yLkOzPFEh\|ryP	M{fTU3NCVkeHUh?=
SR	NGj0UmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnaO3ZKSzVyPUCuN\|QzPjFizszN	MnywV2FPT0WU
CMK	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LSWGlEPTB;MD6zOVczPyEQvF2=	MnXOV2FPT0WU
ES8	NXW2fWRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGr3U41KSzVyPUCuN\|YxOjJizszN	MnnkV2FPT0WU
LB647-SCLC	NXLOOVE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIewPGFKSzVyPUCuN\|Y4OyEQvF2=	MWfTRW5ITVJ?
TE-8	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPvTHFKSzVyPUCuN\|Y6OzVizszN	MX7TRW5ITVJ?
BV-173	NFrVfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnCTWM2OD1yLkO3NVIyKM7:TR?=	MmT2V2FPT0WU
DEL	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwM{e0PFch\|ryP	M3r1RXNCVkeHUh?=
ARH-77	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHxTWM2OD1yLkO4NVk{KM7:TR?=	M1rYbHNCVkeHUh?=
NCCIT	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\nfmlEPTB;MD6zPFY1QSEQvF2=	MojNV2FPT0WU
RPMI-8402	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwM{i3NFEh\|ryP	NEPoTItUSU6JRWK=
MONO-MAC-6	NF7DSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvITWM2OD1yLkO4O\|c3KM7:TR?=	MVjTRW5ITVJ?
SK-MM-2	M1;EbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PD[GlEPTB;MD6zPVg3QCEQvF2=	NHXPWGZUSU6JRWK=
CHP-126	MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3SwXWlEPTB;MD60NFI{OSEQvF2=	M37NXXNCVkeHUh?=
A101D	M3PnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwNECzJO69VQ>?	NHjycWRUSU6JRWK=
SCH	NXLWZYJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVz3S3RKUUN3ME2wMlQxOzR{IN88US=>	M17uNnNCVkeHUh?=
NMC-G1	NHHaVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjSVphKSzVyPUCuOFA{PjdizszN	MUTTRW5ITVJ?
NCI-H209	Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwNEC2NVMh\|ryP	NWPOPGVOW0GQR1XS
MOLT-16	NHy4SZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwNEGwNVch\|ryP	MXLTRW5ITVJ?
RPMI-6666	MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXiSnBuUUN3ME2wMlQyOTJizszN	NVTp[3hjW0GQR1XS
OPM-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUL2[I1JUUN3ME2wMlQyPTF\|IN88US=>	MorMV2FPT0WU
MRK-nu-1	NV3zcpQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXvcoZKSzVyPUCuOFMyPTNizszN	NUPzTFdoW0GQR1XS
BC-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwNEO0NFMh\|ryP	M37aWXNCVkeHUh?=
MHH-NB-11	NEi0bW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PQOWlEPTB;MD60N\|Q2OyEQvF2=	MkjpV2FPT0WU
Ramos-2G6-4C10	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nSb2lEPTB;MD60N\|g6PyEQvF2=	NF;PVWFUSU6JRWK=
LS-513	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwNES1NFEh\|ryP	NGLTOYFUSU6JRWK=
K5	NYrtcm1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwNEewNlUh\|ryP	NIfwcoNUSU6JRWK=
HOP-62	NWfDe496T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPvUlJIUUN3ME2wMlQ5OzV6IN88US=>	MkfyV2FPT0WU
NCI-H187	M{SyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnftTWM2OD1yLkS5NlI4KM7:TR?=	MoK2V2FPT0WU
BE-13	M3W0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwNEm2OlEh\|ryP	NXfU[YhHW0GQR1XS
HC-1	M3rZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTrZohMUUN3ME2wMlUxPDd\|IN88US=>	MYnTRW5ITVJ?
ACN	M331XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonrTWM2OD1yLkWxNFI5KM7:TR?=	MVrTRW5ITVJ?
HCC1599	NX7FN4FsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH2wcndKSzVyPUCuOVE2PyEQvF2=	NIC4O2xUSU6JRWK=
MV-4-11	M4\nW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHkOWpKSzVyPUCuOVMxPDFizszN	MUfTRW5ITVJ?
LC-2-ad	M4fldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXuTWM2OD1yLkWzOlY{KM7:TR?=	NHzSdVRUSU6JRWK=
HL-60	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwNUSyOlEh\|ryP	Mn[zV2FPT0WU
NB17	M3jvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLzZ5FRUUN3ME2wMlU1OzhizszN	NUPLRmpLW0GQR1XS
TE-1	NITCcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PEfmlEPTB;MD61OVMxPiEQvF2=	MlyyV2FPT0WU
NCI-H524	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fHNWlEPTB;MD61OVQxOSEQvF2=	MnOzV2FPT0WU
MZ7-mel	NEL0NmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzyemU2UUN3ME2wMlU3OTB3IN88US=>	MX3TRW5ITVJ?
L-363	M4X2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwNU[2OVch\|ryP	MlexV2FPT0WU
BL-41	M3PMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwNU[4PFkh\|ryP	M1j3cnNCVkeHUh?=
LU-134-A	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrtdYNuUUN3ME2wMlU4ODd\|IN88US=>	NX3pRmFRW0GQR1XS
SIG-M5	NV\UbGt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLxSZJKSzVyPUCuOVc5PDhizszN	NH30VphUSU6JRWK=
ONS-76	Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoL1TWM2OD1yLkW4NlQzKM7:TR?=	MkSyV2FPT0WU
KARPAS-299	MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwNUi1NFQh\|ryP	MWPTRW5ITVJ?
DU-4475	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjjOoRKSzVyPUCuOVg4ODNizszN	MYHTRW5ITVJ?
NB69	NGj0bJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwNUm4NlUh\|ryP	NYT0VlRxW0GQR1XS
MHH-PREB-1	MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLBTWM2OD1yLk[wO\|E6KM7:TR?=	NFf5T21USU6JRWK=
LU-165	NFfrOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTBwNkG4NVIh\|ryP	M{jqcnNCVkeHUh?=
LOUCY	NWC3O2dKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwNkOzOlQh\|ryP	NYjrOoFrW0GQR1XS
NCI-H526	M4D4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmG0TWM2OD1yLk[zOVQyKM7:TR?=	NUj1OXJzW0GQR1XS
KE-37	Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwNkSyO\|Yh\|ryP	M{jm[HNCVkeHUh?=
NALM-6	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwNkS4OkDPxE1?	Mn\UV2FPT0WU
CW-2	NF\CVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mon5TWM2OD1yLk[1O\|k1KM7:TR?=	MmTEV2FPT0WU
SU-DHL-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn6zTWM2OD1yLk[1PVQ4KM7:TR?=	MUnTRW5ITVJ?
NB13	NGrocm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonJTWM2OD1yLk[2PFE4KM7:TR?=	NHjme4ZUSU6JRWK=
QIMR-WIL	MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITLTpdKSzVyPUCuOlg{PDNizszN	M4q1VnNCVkeHUh?=
ECC12	M2jSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwN{CwPFYh\|ryP	MojHV2FPT0WU
KALS-1	M1zBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEOzellKSzVyPUCuO\|A1QTJizszN	NE\2Wm1USU6JRWK=
COR-L279	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwN{C5PVYh\|ryP	M33WZXNCVkeHUh?=
NB14	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlr5TWM2OD1yLkeyOlE4KM7:TR?=	M3TDTXNCVkeHUh?=
CCRF-CEM	NH;PS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfsNnZKSzVyPUCuO\|Q3PjFizszN	NF\WV49USU6JRWK=
SW954	Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXj0OGJiUUN3ME2wMlc2QTl7IN88US=>	NGHSeIJUSU6JRWK=
IST-SL1	MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXBTWM2OD1yLke3N\|Q5KM7:TR?=	MU\TRW5ITVJ?
LAMA-84	NVzVZYZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\teWlEPTB;MD63O\|U3PyEQvF2=	MmHxV2FPT0WU
Daudi	NHrTVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPxe4dKSzVyPUCuO\|c3QDFizszN	NU\wXJVbW0GQR1XS
BC-3	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XwOWlEPTB;MD63PFMxQCEQvF2=	MXTTRW5ITVJ?
HCC2998	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYC2WIh2UUN3ME2wMlc5OzZizszN	NVHjR217W0GQR1XS
NCI-H69	M{Tn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGWySG1KSzVyPUCuPFAyPDdizszN	M333XnNCVkeHUh?=
CPC-N	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwOEC1NlQh\|ryP	M1Hae3NCVkeHUh?=
NOMO-1	NWDyRVh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\YTWM2OD1yLkixNFg1KM7:TR?=	NWHlU4J1W0GQR1XS
CESS	MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4f5b2lEPTB;MD64NVE6PyEQvF2=	M1PtR3NCVkeHUh?=
LC4-1	Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPVUphKSzVyPUCuPFQxODdizszN	Ml\hV2FPT0WU
BL-70	NUjC[lFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\LXJlqUUN3ME2wMlg2PzB{IN88US=>	MkPwV2FPT0WU
ES4	NGTI[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwOEW4Olgh\|ryP	M4PTWXNCVkeHUh?=
HCE-T	M4LufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwOEexO\|Eh\|ryP	NI\JN2NUSU6JRWK=
JAR	NGXLW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDUTWM2OD1yLki3PFI4KM7:TR?=	NUDsTIhUW0GQR1XS
ST486	NWXoUJJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3GweGlEPTB;MD64O\|kyPyEQvF2=	MmTEV2FPT0WU
KS-1	NYS2[oRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXjdJJKSzVyPUCuPFgxQTZizszN	NHK3dFBUSU6JRWK=
GDM-1	NU\FcVJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjVNHRUUUN3ME2wMlg5Pjh5IN88US=>	MoK0V2FPT0WU
EHEB	NXPDSWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1eyWGlEPTB;MD65NlU5PSEQvF2=	MXHTRW5ITVJ?
LB2518-MEL	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkmxTWM2OD1yLkmzNlg1KM7:TR?=	Mkn5V2FPT0WU
GOTO	M{HrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwOUWwO\|Yh\|ryP	NGqwdGRUSU6JRWK=
LXF-289	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwOUW5NFEh\|ryP	NYnjSoN6W0GQR1XS
ES6	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3KxV2lEPTB;MD65OlQ{PyEQvF2=	MU\TRW5ITVJ?
OS-RC-2	M{XoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rNWGlEPTB;MD65Olg{KM7:TR?=	NWDpbmlSW0GQR1XS
DMS-153	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzyTWM2OD1yLkm3OFY6KM7:TR?=	MY\TRW5ITVJ?
SK-PN-DW	NEjRN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnCOYZDUUN3ME2wMlk4QDNzIN88US=>	NHm4UFBUSU6JRWK=
HH	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LsNWlEPTB;MD65PFk2QSEQvF2=	NW\JepIyW0GQR1XS
SH-4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn76TWM2OD1zLkCyOFEh\|ryP	M4XJVnNCVkeHUh?=
MOLT-4	NXnBVYsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XmN2lEPTB;MT6wN\|Q2PCEQvF2=	MWfTRW5ITVJ?
TGW	NVX1dmFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTFwMEe2O\|Uh\|ryP	NGr5U2xUSU6JRWK=
L-540	NF\PU\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7IOVNKSzVyPUGuNVA3ODRizszN	MorFV2FPT0WU
PF-382	NEnxblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTFwMUG1NVMh\|ryP	MYPTRW5ITVJ?
LC-1F	NUHhbIR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4O3RWlEPTB;MT6xNlAxPyEQvF2=	MoWxV2FPT0WU
OVCAR-4	NELNb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYOyS\|I{UUN3ME2xMlE{OTZ3IN88US=>	NYLTV4xNW0GQR1XS
A4-Fuk	Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTFwMUWzOlQh\|ryP	MWrTRW5ITVJ?
HCC2218	M2Pxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PHN2lEPTB;MT6xOlY1OSEQvF2=	NV;heoVbW0GQR1XS
HAL-01	NH3Zc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\Sfos2UUN3ME2xMlE3QTR\|IN88US=>	NVnwNoN5W0GQR1XS
IST-MEL1	NYPSZpJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\KeWdxUUN3ME2xMlE4PjV7IN88US=>	NGfoPHVUSU6JRWK=
NCI-H719	M1rQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHiwb3dKSzVyPUGuNVc5QThizszN	NXu4eoNvW0GQR1XS
EVSA-T	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTPTYxKSzVyPUGuNVgyOTRizszN	Mn\yV2FPT0WU
SK-NEP-1	NVrLS49GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYO0U3JJUUN3ME2xMlIxOjZ4IN88US=>	MnXUV2FPT0WU
OCUB-M	M2XqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\HbYtKSzVyPUGuNlE1QDlizszN	MXHTRW5ITVJ?
MEG-01	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVz0XpFZUUN3ME2xMlIzOTF6IN88US=>	M1Pab3NCVkeHUh?=
no-10	NXLGfnpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\CT2Y3UUN3ME2xMlI{OTF{IN88US=>	M3n3[XNCVkeHUh?=
MHH-CALL-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTFwMkS3NlEh\|ryP	M1jIcXNCVkeHUh?=
SK-N-DZ	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LGZWlEPTB;MT6yOFc4PiEQvF2=	NETMdppUSU6JRWK=
SCLC-21H	M1u4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYG0eYc3UUN3ME2xMlI3PDd6IN88US=>	Ml3QV2FPT0WU
CTV-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFn0V3VKSzVyPUGuNlc1OjVizszN	MX3TRW5ITVJ?
NB1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHrZ5hKSzVyPUGuNlc4OzJizszN	MoXhV2FPT0WU
NCI-H64	NV\aUm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLvTWM2OD1zLkK4OFYzKM7:TR?=	MXnTRW5ITVJ?
MDA-MB-134-VI	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2G3XWlEPTB;MT6yPFU4PyEQvF2=	NGm4N\|dUSU6JRWK=
LB2241-RCC	M3jXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjXUWk{UUN3ME2xMlI5PjZ\|IN88US=>	NX\sUWJrW0GQR1XS
8-MG-BA	Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIftfFlKSzVyPUGuNlg5PjZizszN	MUXTRW5ITVJ?
LP-1	NVfw[noxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHiw[WVKSzVyPUGuNlk6PDdizszN	M4LHUnNCVkeHUh?=
LS-411N	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LhVmlEPTB;MT6zNFk6QCEQvF2=	NYHRZ3NWW0GQR1XS
CAL-148	Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnZXHplUUN3ME2xMlMzPTR{IN88US=>	MonlV2FPT0WU
NCI-H2171	NUTjSpRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrZbWhKSzVyPUGuN\|Q2ODJizszN	M2PU[XNCVkeHUh?=
JiyoyeP-2003	NXXr[YRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnDTWM2OD1zLkO1N\|kh\|ryP	M3\n[nNCVkeHUh?=
NCI-H2107	M{LOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXe1cVY5UUN3ME2xMlM2QDh\|IN88US=>	NIL1OFVUSU6JRWK=
BB30-HNC	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPoTXo5UUN3ME2xMlM5QTd6IN88US=>	MWrTRW5ITVJ?
K-562	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTFwM{myNVkh\|ryP	MmLkV2FPT0WU
PSN1	M4PhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPJcFlKSzVyPUGuOFIzQDdizszN	MXfTRW5ITVJ?
HCC2157	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\YXVVvUUN3ME2xMlQzPjlzIN88US=>	MnPaV2FPT0WU
SBC-1	NEjqW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmiyTWM2OD1zLkSyO\|QyKM7:TR?=	NV3oOGVwW0GQR1XS
MC116	NGPL[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzCWpBkUUN3ME2xMlQ{PjF3IN88US=>	M1i3PHNCVkeHUh?=
KARPAS-422	MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLCTWM2OD1zLkS1N\|U5KM7:TR?=	Mn7oV2FPT0WU
LB996-RCC	M2fsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYC0co1PUUN3ME2xMlQ4OTB\|IN88US=>	MmLwV2FPT0WU
MSTO-211H	NF\BdXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHi2enJKSzVyPUGuOFc6QDdizszN	NX3icW9wW0GQR1XS
BT-474	NXf1[no4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonzTWM2OD1zLkWxO\|Y1KM7:TR?=	NUTPPVc5W0GQR1XS
A388	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHj4NotKSzVyPUGuOVE6PDVizszN	NX\VSnVJW0GQR1XS
SJSA-1	NUfIR4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3v4N2lEPTB;MT61NlI3KM7:TR?=	NXfaVnBVW0GQR1XS
COLO-829	NE\MW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoL3TWM2OD1zLkWzOVY1KM7:TR?=	MlS4V2FPT0WU
KM-H2	Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTFwNU[2O{DPxE1?	NFT5dHJUSU6JRWK=
GR-ST	M2PCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTFwNU[4NkDPxE1?	NWjYOlVWW0GQR1XS
RPMI-8866	NFr6dZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzofYhKSzVyPUGuOlAyPDRizszN	NYLZS3ZSW0GQR1XS
KG-1	NFzJfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1SyXGlEPTB;MT62NVkxOSEQvF2=	NVzDXIZyW0GQR1XS
NCI-H82	Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HPUWlEPTB;MT62N\|QxPiEQvF2=	NFzIT21USU6JRWK=
LB1047-RCC	M2jEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHNdWgxUUN3ME2xMlY{PDV7IN88US=>	MVrTRW5ITVJ?
KM12	NUX1RlBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzLZodKSzVyPUGuOlQ4KM7:TR?=	NYjW[2FqW0GQR1XS
NB5	NIHjUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWX6O2kyUUN3ME2xMlY2Pjd5IN88US=>	NWj5SmxtW0GQR1XS
HDLM-2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFwNkiyPFEh\|ryP	MWHTRW5ITVJ?
KU812	NWm2UYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\2fnpKSzVyPUGuOlk3ODVizszN	NGjM[llUSU6JRWK=
DB	NFPRbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrLbpBjUUN3ME2xMlcxOzV\|IN88US=>	NIjpRYZUSU6JRWK=
HD-MY-Z	NEDUS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnmT\|ZKSzVyPUGuO\|UzOzRizszN	NGnGco9USU6JRWK=
KURAMOCHI	NWWxe\|ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LmSmlEPTB;MT63O\|IxPyEQvF2=	M{TCbHNCVkeHUh?=
ETK-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTFwN{i4O\|kh\|ryP	MortV2FPT0WU
SK-UT-1	MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTFwN{mzPFgh\|ryP	MXvTRW5ITVJ?
HUTU-80	NIizdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPafXFEUUN3ME2xMlc6PTB6IN88US=>	NXrLc41tW0GQR1XS
ES7	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\WZolyUUN3ME2xMlgxOzB{IN88US=>	NG[zfWlUSU6JRWK=
SW872	NXXp[XlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzlTWM2OD1zLkixN\|k2KM7:TR?=	M3nNdnNCVkeHUh?=
TK10	NX;qXGNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2r4RWlEPTB;MT64N\|ExQCEQvF2=	NVHrOpRtW0GQR1XS
LB831-BLC	NV7GTlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTFwOEO1OlMh\|ryP	M1LKZnNCVkeHUh?=
TE-9	MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTFwOES0NlIh\|ryP	MVPTRW5ITVJ?
MLMA	NHSz[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHwZ29KSzVyPUGuPFgzOzRizszN	MWDTRW5ITVJ?
D-542MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;reWlEPTB;MT64PVM4OyEQvF2=	NYn1dmlCW0GQR1XS
EW-16	NEC1cIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrYVVFKSzVyPUGuPVI4OiEQvF2=	MWDTRW5ITVJ?
LOXIMVI	MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTFwOUOyPEDPxE1?	NHnybFhUSU6JRWK=
GB-1	M1PmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPSTWlvUUN3ME2xMlk{QDZ4IN88US=>	M{T3[nNCVkeHUh?=
IST-SL2	MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PWdWlEPTB;Mj6wNFI3OiEQvF2=	M4W3SnNCVkeHUh?=
LAN-6	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXT0blNrUUN3ME2yMlAyQTZ4IN88US=>	NUTocmk4W0GQR1XS
NCI-H510A	NVi5N2tuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLEdXU1UUN3ME2yMlA1PTB{IN88US=>	MW\TRW5ITVJ?
NCI-H1092	NXzXRpBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDHTWM2OD1{LkC1NVI1KM7:TR?=	MljRV2FPT0WU
HT	NW\6dnJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVOyfnlSUUN3ME2yMlExPDV2IN88US=>	MXXTRW5ITVJ?
RL95-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHi[m1KSzVyPUKuNVE1QDJizszN	NIPiTopUSU6JRWK=
NCI-H1355	Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfiRWFDUUN3ME2yMlEyPzl{IN88US=>	M1\HSXNCVkeHUh?=
NCI-H720	NWTuRZV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTJwMU[4O\|Mh\|ryP	MoLHV2FPT0WU
NCI-H1522	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPhXXRKSzVyPUKuNlE4OjNizszN	NHHJd\|NUSU6JRWK=
LB373-MEL-D	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTJwMk[5NFIh\|ryP	NF;vNZlUSU6JRWK=
DG-75	NHnDTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHmN4tKSzVyPUKuNlcyPDhizszN	NF[0RpJUSU6JRWK=
ML-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFyxfGhKSzVyPUKuN\|I5PTVizszN	M364eXNCVkeHUh?=
SF126	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{n2VGlEPTB;Mj6zN\|A6PCEQvF2=	Mn3uV2FPT0WU
MPP-89	M1jLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTJwM{OxOFUh\|ryP	MVfTRW5ITVJ?
NCI-H345	M1jqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYroRm43UUN3ME2yMlM{Ojd5IN88US=>	MWDTRW5ITVJ?
LS-123	M33VOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVi5fphXUUN3ME2yMlM1QTN4IN88US=>	NWGxeWJKW0GQR1XS
NB10	NUHsRZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTJwNEGwPVIh\|ryP	MXXTRW5ITVJ?
CGTH-W-1	M17qb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjpclZLUUN3ME2yMlQzOjZ5IN88US=>	NUjHXnB7W0GQR1XS
CP66-MEL	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTJwNEe3O{DPxE1?	NHLsOVVUSU6JRWK=
L-428	NUW0N5p7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjCTWM2OD1{LkS4OVIyKM7:TR?=	Ml7vV2FPT0WU
DMS-79	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWiyNFRVUUN3ME2yMlU1OTB\|IN88US=>	NV[5UpV1W0GQR1XS
NCI-H1882	NXXSPFlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTJwNke1OlIh\|ryP	M3nLXXNCVkeHUh?=
KGN	NXH1c2VVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\LW\|F4UUN3ME2yMlc3QDd4IN88US=>	NWTOSJo{W0GQR1XS
EW-1	NH:0WIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTJwN{ewPFMh\|ryP	MVHTRW5ITVJ?
U-266	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTOTWM2OD1{Lki0PFI{KM7:TR?=	NX25TnJ3W0GQR1XS
COLO-320-HSR	M2SyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;wVWlEPTB;Mj64OVY1OSEQvF2=	M2DE[nNCVkeHUh?=
KMOE-2	Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXwTWM2OD1{Lki3O\|EyKM7:TR?=	MXvTRW5ITVJ?
BB49-HNC	M13vXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\vTWM2OD1{LkmyOFgh\|ryP	MXfTRW5ITVJ?
GI-1	NF7BNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjJ[I5KSzVyPUKuPVI6PTdizszN	M{HlOnNCVkeHUh?=
NCI-H1304	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnlT5ZKSzVyPUOuNFA2OTFizszN	NH6wW5BUSU6JRWK=
NCI-H2227	NXfMe3NzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXYS2VKSzVyPUOuNFIxPzlizszN	NGPCZYdUSU6JRWK=
U-87-MG	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfTPW5KSzVyPUOuNFM2OTNizszN	M{HER3NCVkeHUh?=
NCI-H747	NUXHbmk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\nTHhKSzVyPUOuNFUzODZizszN	M2\wdnNCVkeHUh?=
CTB-1	M17sSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVy0WnB7UUN3ME2zMlA2Ozd4IN88US=>	MWrTRW5ITVJ?
RPMI-8226	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NICyZmZKSzVyPUOuNVQ{PzhizszN	NXTNSWlEW0GQR1XS
NCI-H2141	M3r0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\MS2lEPTB;Mz6xOlU3PiEQvF2=	NEXZRVRUSU6JRWK=
IST-MES1	M1m5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTNwMUiyO\|kh\|ryP	NIHmXGtUSU6JRWK=
TE-5	M4XRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LZPWlEPTB;Mz6yNVM1OiEQvF2=	MnfUV2FPT0WU
UACC-257	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTNwNEO2OVkh\|ryP	MWnTRW5ITVJ?
SK-N-FI	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moj2TWM2OD1\|LkS1NlI4KM7:TR?=	NWDZNphVW0GQR1XS
MFH-ino	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrEN41KSzVyPUOuOFY2QDlizszN	M1fLb3NCVkeHUh?=
SF268	MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HlfGlEPTB;Mz60PFE4PCEQvF2=	MnW4V2FPT0WU
TE-12	NWTjWIVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\5TWM2OD1\|LkWxOlk6KM7:TR?=	Mn24V2FPT0WU
NB6	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnI[IJKSzVyPUOuOVU2PjNizszN	MVLTRW5ITVJ?
DJM-1	NFKxVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LGeGlEPTB;Mz61PVg6QSEQvF2=	NFfUc45USU6JRWK=
MZ1-PC	M33HNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzJSopIUUN3ME2zMlYyPjJ2IN88US=>	MlPzV2FPT0WU
OCI-AML2	NF72R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\aTWM2OD1\|Lk[yOlcyKM7:TR?=	NWnPZY95W0GQR1XS
NCI-H1155	M2XqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfTdWE3UUN3ME2zMlcxQTR5IN88US=>	MV\TRW5ITVJ?
RKO	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTNwN{exPFkh\|ryP	NVS3cpA2W0GQR1XS
ECC4	NXH3V5liT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MluyTWM2OD1\|Lkm3NVk2KM7:TR?=	NYD2[HJjW0GQR1XS
BB65-RCC	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTNwOUe1OFch\|ryP	M1i2UHNCVkeHUh?=
EB-3	NUf1cIxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrlSIZKSzVyPUOuPVk3OzNizszN	NHnVdGtUSU6JRWK=
SHP-77	NFvBW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLiR5d[UUN3ME20MlAxPTJ2IN88US=>	M1rUXnNCVkeHUh?=
NCI-H2196	NF62UGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnf0TWM2OD12LkC1OlI2KM7:TR?=	NEPGUVdUSU6JRWK=
GI-ME-N	MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHjXVVKSzVyPUSuNFY{QTlizszN	MUjTRW5ITVJ?
MN-60	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTRwMUC4O{DPxE1?	M3\KUXNCVkeHUh?=
NCI-H1694	NXPWc2s5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\je\|dKSzVyPUSuNVM1ODVizszN	MnXEV2FPT0WU
LU-65	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrETWM2OD12LkG1N\|MzKM7:TR?=	NX\0XFhbW0GQR1XS
NCI-H1436	NGTiRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PJfmlEPTB;ND6xPFM{OyEQvF2=	MXLTRW5ITVJ?
KINGS-1	NYO3PIZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnETWM2OD12LkOxOFMzKM7:TR?=	Ml\4V2FPT0WU
GT3TKB	NIrCVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2W5RWlEPTB;ND6zN\|I3QCEQvF2=	MWnTRW5ITVJ?
Becker	M1PEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlq3TWM2OD12LkO3N\|EzKM7:TR?=	NFLGOFZUSU6JRWK=
HCC1187	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYT6UWpSUUN3ME20Mlg6PjV5IN88US=>	NHTOUFBUSU6JRWK=
D-502MG	NFe4T29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2Dl[WlEPTB;NT6wNFQyPiEQvF2=	MULTRW5ITVJ?
VA-ES-BJ	MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrNTWM2OD13LkGzO\|c5KM7:TR?=	M1zaXXNCVkeHUh?=
NB7	NITJeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTVwMUSxNVIh\|ryP	NXPTWFFiW0GQR1XS
SW962	NYG0Omk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHmyPINKSzVyPUWuN\|g5OTRizszN	M3m4XnNCVkeHUh?=
no-11	M3j0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXjZ5ZjUUN3ME21Mlc3OzR\|IN88US=>	NYDQVVN{W0GQR1XS
KNS-81-FD	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjZS3JKSzVyPUWuPVA3QTRizszN	M1LnN3NCVkeHUh?=
COLO-684	NHPDe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnOTWM2OD13Lkm5OFk1KM7:TR?=	M{noNHNCVkeHUh?=
D-263MG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoKzTWM2OD14LkC4PFk2KM7:TR?=	Ml3wV2FPT0WU
EW-24	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTZwMki1NUDPxE1?	NV;qc257W0GQR1XS
TE-10	M4LqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnMeJpKSzVyPU[uOFI3OjNizszN	NH;xTHNUSU6JRWK=
EKVX	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q5U2lEPTB;Nj60OlMzOSEQvF2=	MlTpV2FPT0WU
NCI-H1648	NITSbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPXTWM2OD14Lk[3OVU4KM7:TR?=	NVrU[XZpW0GQR1XS
LB771-HNC	NHvNVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nMNmlEPTB;Nj65NlMxOSEQvF2=	M{n0Z3NCVkeHUh?=
SK-MEL-1	M2LHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRThwMUOxOlYh\|ryP	M2nxU3NCVkeHUh?=
COLO-668	M3:xcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHsWIRwUUN3ME24MlI4Pzh4IN88US=>	NYfBU5VjW0GQR1XS
EW-12	NWPp[m1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XEO2lEPTB;OD60NFgxOyEQvF2=	NEfMdopUSU6JRWK=
A253	NX7RNYg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHhdFJvUUN3ME24Mlg1PjZzIN88US=>	MnzVV2FPT0WU
NCI-H2126	M3fVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TBW2lEPTB;OD64PVMyQSEQvF2=	NXrOS4NFW0GQR1XS
Calu-6	NFuwNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoC4TWM2OD16Lkm5NFQzKM7:TR?=	MXPTRW5ITVJ?
NCI-H23	M1f6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTlwMUe3OFYh\|ryP	MX;TRW5ITVJ?
WSU-NHL	NH7sXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTlwN{e0O\|gh\|ryP	MorIV2FPT0WU
MMAC-SF	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\pc2lEPTB;OT65O\|kxPCEQvF2=	MU\TRW5ITVJ?
SK-LMS-1	NXy4WGFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTFyLkK4N\|Qh\|ryP	NEDoeZhUSU6JRWK=
GCIY	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3X2dmlEPTB;MUCuOVkzPCEQvF2=	M4rLOHNCVkeHUh?=
TE-15	Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;VTWM2OD1zMT62NFA1KM7:TR?=	M{PlOXNCVkeHUh?=
EoL-1-cell	NEfDb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfYfmhKSzVyPUGxMlc3QDJizszN	NVXReGdOW0GQR1XS
NCI-H2081	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3ifXVFUUN3ME2xNU44Pzh4IN88US=>	MVPTRW5ITVJ?
EW-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLZR2pKSzVyPUGyMlI1PjNizszN	NIPhXGpUSU6JRWK=
CAS-1	M4SxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfiTWM2OD1zMj6zOlMyKM7:TR?=	NEnmcItUSU6JRWK=
C2BBe1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTF{Lk[xN\|Eh\|ryP	NEG2XFlUSU6JRWK=
D-247MG	MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTF{Lke5OVIh\|ryP	MnLnV2FPT0WU
NCI-SNU-5	NF;5fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTF{LkiwNVMh\|ryP	MX3TRW5ITVJ?
LS-1034	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LZO2lEPTB;MUSuN\|k4PSEQvF2=	MmPwV2FPT0WU
EW-18	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3e1[mlEPTB;MUSuOFQ5KM7:TR?=	MXHTRW5ITVJ?
Raji	MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTF2LkWwOFkh\|ryP	M3TsWHNCVkeHUh?=
D-283MED	NUjSeWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrJeJVKSzVyPUG0MlYzPzFizszN	M{e2WHNCVkeHUh?=
MZ2-MEL	M2TMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTF2Lkm2PVYh\|ryP	NGHNcVBUSU6JRWK=
NCI-SNU-16	NF\UWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTF3LkS2N\|Mh\|ryP	M3vjfHNCVkeHUh?=
P30-OHK	M1\sVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWe3bIFNUUN3ME2xO{44QDNzIN88US=>	Mn7ZV2FPT0WU
RXF393	MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLXTWM2OD1zOT6wNVg3KM7:TR?=	Mmj2V2FPT0WU
NCI-H1395	M3f2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;1VGw4UUN3ME2yNE43PzB\|IN88US=>	MmTwV2FPT0WU
U-698-M	NXTYRmRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPJTWM2OD1{MD63NFc2KM7:TR?=	NYL0Tmh4W0GQR1XS
NCI-SNU-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;GTGlEPTB;MkCuO\|IzOyEQvF2=	M3:wSXNCVkeHUh?=
SW684	M3i5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M16ybmlEPTB;MkGuNVcyPiEQvF2=	NH3rVYFUSU6JRWK=
NCI-H716	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHpTWM2OD1{MT6zNVU1KM7:TR?=	M3jYV3NCVkeHUh?=
JVM-2	NHy4OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTJzLkSxN\|Mh\|ryP	NX\JPWFYW0GQR1XS
NCI-H1581	NUnpbZB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkD1TWM2OD1{Mj60NVQ5KM7:TR?=	NFPBNZRUSU6JRWK=
CA46	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXX[5VKSzVyPUOxMlY6OzZizszN	NYjsNo1FW0GQR1XS
SNB75	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37sSWlEPTB;M{OuOlUxOyEQvF2=	MWDTRW5ITVJ?
KNS-42	NEPtU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLofIpPUUN3ME2zOU46PjJ2IN88US=>	NX6wN4lnW0GQR1XS
TUR	MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PScGlEPTB;M{[uNFUzOSEQvF2=	Mn72V2FPT0WU
REH	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzHflJKSzVyPUO3MlgzOTFizszN	M2LMbHNCVkeHUh?=
EW-22	NH6zW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPXbldsUUN3ME20Nk4zQDh3IN88US=>	NWDoZZFFW0GQR1XS
NCI-H446	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4f0OWlEPTB;NEKuO\|g2OyEQvF2=	MVzTRW5ITVJ?
ES3	NXfhOZloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnic2EzUUN3ME20N{4yOzN7IN88US=>	MXfTRW5ITVJ?
EW-11	NVzvN5lrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTR2LkiyNVgh\|ryP	MYXTRW5ITVJ?
RH-1	NEnXc\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlf3TWM2OD12Nz61PFEzKM7:TR?=	MmmwV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

In vivo

MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. ^[1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. ^[4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. ^[5]

Protocol

Kinase Assay: ^[6]	- Collapse Standard HDAC Assays: Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λ_ex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. K_m and V_max values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research: ^[2]	- Collapse Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells Concentrations: ~ 10 μM Incubation Time: 3 days Method: Cancer cells (5 × 10³) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO₂-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na₂HPO₄ is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice. Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80 Dosages: 12.3, 24.5 and 49 mg/kg Administration: Administered orally once daily 5 days per week for 4 weeks (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Entinostat (MS-275) SDF

Molecular Weight	376.41
Formula	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SNDX-275
Smiles	NC1=CC=CC=C1NC(=O)C2=CC=C(CNC(=O)OCC3=CN=CC=C3)C=C2

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03829930	Recruiting	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Recruiting	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1
NCT03192111	Completed	Drug: Entinostat	Renal Impairment\|Healthy Volunteer	Syndax Pharmaceuticals	July 27 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
Answer:
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)